November 20, 2025 — Leads & Copy — Wellgistics Health, Inc. (NASDAQ:WGRX) reported its financial results for the period ending September 30, 2025, in a Form 10-Q filed on November 19, 2025, and provided a business update from the CEO.
Prashant Patel, RPh, President and Interim-CEO of Wellgistics Health, stated that after being reappointed as President and Interim-CEO on October 6, 2025, he has gained a better understanding of the business’s different stages of development over the last six weeks. The sales team’s primary focus has been centered on launching Brenzavvy® for the Type 2 diabetes market, which affects over 33 million Americans.
Wellgistics has developed a program using its EinsteinRx™ AI pharmacy hub software to significantly reduce out-of-pocket costs for patients, as only a small percentage currently have access to SGLT-2 inhibitor drugs due to cost constraints. The company anticipates that a successful commercial launch of EinsteinRx™ may contribute meaningfully to future revenue growth. Patel also commended Chief Technology Officer Srini Kalla and the technology team for their work in finalizing EinsteinRx and preparing it for launch. He emphasized the importance of the tech team’s ability to seamlessly implement the software for clients for long-term success.
According to Patel, the third quarter saw significant equity-based expenses tied to the pre-IPO acquisition of the pharmaceutical distribution business unit. The company’s go-forward approach will center on the staged integration of EinsteinRx throughout its customers’ value chains. Wellgistics intends to put EinsteinRx onto the PharmcyChain™ smart contracts platform in 2026. The company believes this platform will provide better data to optimize patient outcomes while reducing costs for payers, and they are in advanced discussions with DataVault AI (NASDAQ:DVLT) to complete a license agreement by the first quarter of 2026.
In the U.S. prescription drug market, Wellgistics’ proposed acquisition of Kare Hub Rx will provide optimized telepharmacy integration software, allowing telehealth providers to route prescriptions through its online pharmacy. This acquisition creates a competitive edge in the GLP-1 offering business to pharmacies and telehealth companies. In March, Wellgistics partnered with Tollo Health to provide prescription-complementary products that address major GLP-1 side effects, which are expected to become commercially available in the United States soon.
The GLP-1 drug market is currently valued at $53 billion annually and is expected to reach $156 billion by 2030, according to Grandview Research. Wellgistics eventually aims to offer all GLP-1 drugs to pharmacy clients and through its online pharmacy at competitive prices, while also selling cash-pay side effect-mitigating medical foods.
The first GLP-1 side effect product to mitigate muscle loss is expected to launch in the first quarter of 2026. The company has also begun distributing 3CL protease inhibitor cleansing supplement Tollovid™ targeting Long COVID to select physicians. The CDC reported that over 17 million Americans were living with Long COVID in 2024, and Wellgistics expects certain Long COVID clinicians to begin making Tollovid available for their patients this month. After Thanksgiving, the company plans to launch the first natural antiviral combo, Tollovid and Galectovid™, to pharmacies. Wellgistics intends to expand its prescription drug catalog to include drugs frequently prescribed for Long COVID.
Lastly, the acquisition of Peek Healthcare Technologies, Inc. has been terminated, as it no longer strategically aligns with Wellgistics’ future plans.
The company recorded a net operating loss of $33.878 million in the third quarter of 2025, compared to a net operating loss of $1.867 million in the third quarter of 2024. The increase in net loss was primarily due to increased stock-based compensation. Net loss per share in the third quarter of 2025 was $0.46 based on 74.379 million weighted average shares outstanding, compared to a net loss of $0.04 per share on 48.403 million weighted average shares outstanding in the third quarter of 2024.
Contact:
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.com
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com
Source: Wellgistics Health, Inc.
